Telmisartan consistently reduced cell proliferation and cell viability in all three endometrial cancer cell lines and was more effective than either a renin inhibitor, a sole ARB (losartan), or a sole PPAR-γ agonist. This evidence concerns the gene REN and endometrial cancer.